BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data

• A single 60 mg dose raised average AAT levels to 16.1 microns, with all patients staying above the protective threshold for up to 12 months.
• The treatment converted 94% of AAT in the blood into the healthy form.
• The company said it expects to file an IND with the FDA advancing BEAM-304, a liver-targeted gene-editing therapy, later in 2026.

Shares of Beam Therapeutics Inc (BEAM) gave up most of their early gains to trade 1% higher on Wednesday, after the biotech firm reported promising early-stage data for its gene-editing therapy (BEAM-302) that showed the candidate with alpha-1 antitrypsin deficiency (AAT) could sustain protective protein levels for up to one year. This reinforces the case for durable one-time genetic therapies for rare liver diseases. 

According to the report, a single 60 mg dose raised average AAT levels to 16.1 microns (µM), with all patients staying above the protective threshold for up to 12 months. The treatment converted 94% of AAT in the blood into the healthy form and reduced the harmful mutant protein by 84%.

Beam Selects 60 mg As Optimal Dose

Patients also retained the ability to boost AAT levels during infections, the company added. The treatment was well tolerated across doses up to 75 mg, with no serious safety concerns reported. Based on the results, Beam selected 60 mg as the optimal dose and announced plans to begin a global trial in the second half of 2026.

“What makes BEAM-302 particularly compelling is its ability to directly correct the underlying genetic mutation in the SERPINA1 gene that drives both lung and liver manifestations of the disease. By enabling the liver to produce corrected M-AAT for the first time while reducing the toxic mutant protein, this approach has the potential to fundamentally transform how we as clinicians treat AATD and represents a meaningful advance for patients,” said said Jeffrey Teckman, professor of pediatrics, Saint Louis University School of Medicine.

Retail sentiment for BEAM on Stocktwits turned ‘bullish’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.

Phenylketonuria Treatment Update

Last month, Beam Therapeutics said it is advancing BEAM-304, a liver-targeted gene-editing therapy designed to treat Phenylketonuria (PKU) by correcting mutations in the PAH gene. The therapy aims to reduce toxic phenylalanine levels and potentially free patients from strict diets and medical foods.

Preclinical studies showed promising results, with normalized phenylalanine levels in animal models. Beam plans to file an IND with the U.S. Food and Drug Administration (FDA) this year and begin a Phase 1/2 trial targeting common genetic variants.

Year-to-date, the stock fell around 14%.

Get updates to this developing story on Stocktwits.

For updates and corrections, email newsroom[at]stocktwits[dot]com.